NCT01970553View on ClinicalTrials.gov

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Specific Advanced Solid Tumors
Interventions
DRUG

lurbinectedin (PM01183)

lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials

DRUG

Gemcitabine

1000 mg vial, powder for injectable solution

Trial Locations (3)

Unknown

Hospital Universitario Madrid Sanchinarro, Madrid

Hospital Universitario Virgen del Rocio, Seville

University College of London Hospital, London

Sponsors

Lead Sponsor

PharmaMar
All Listed Sponsors
lead

PharmaMar

INDUSTRY

NCT01970553 - Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors | Biotech Hunter | Biotech Hunter